Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;93(9):5285-5294.
doi: 10.1002/jmv.27075. Epub 2021 May 19.

Vitamin D and COVID-19: Role of ACE2, age, gender, and ethnicity

Affiliations
Review

Vitamin D and COVID-19: Role of ACE2, age, gender, and ethnicity

Bruk Getachew et al. J Med Virol. 2021 Sep.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, disproportionally targets older people, particularly men, ethnic minorities, and individuals with underlying diseases such as compromised immune system, cardiovascular disease, and diabetes. The discrepancy in COVID-19 incidence and severity is multifaceted and likely involves biological, social, as well as nutritional status. Vitamin D deficiency, notably common in Black and Brown people and elderly, is associated with an increased susceptibility to many of the diseases comorbid with COVID-19. Vitamin D deficiency can cause over-activation of the pulmonary renin-angiotensin system (RAS) leading to the respiratory syndrome. RAS is regulated in part at least by angiotensin-converting enzyme 2 (ACE2), which also acts as a primary receptor for SARS-CoV-2 entry into the cells. Hence, vitamin D deficiency can exacerbate COVID-19, via its effects on ACE2. In this review we focus on influence of age, gender, and ethnicity on vitamin D-ACE2 interaction and susceptibility to COVID-19.

Keywords: SARS-CoV-2; angiotensin-converting enzyme 2 (ACE2); co-morbidity-COVID-19; cytokine Storm; vitamin D deficiency.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Similar articles

Cited by

References

    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China. JAMA. 2020;323:1239‐1242. 10.1001/jama.2020.2648 - DOI - PubMed
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507‐513. 10.1016/s0140-6736(20)30211-7 - DOI - PMC - PubMed
    1. Lips P, Cashman KD, Lamberg‐Allardt C, et al. Management of endocrine disease: current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency; a position statement of the European Calcified Tissue Society. Eur J Endocrinol. 2019;180:23‐54. - PubMed
    1. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta‐analysis. Int J Infect Dis. 2020;94:91‐95. 10.1016/j.ijid.2020.03.017 - DOI - PMC - PubMed
    1. Panarese A, Shahini E. Letter: COVID‐19, and vitamin D. Aliment Pharmacol Ther. 2020;51:993‐995. - PMC - PubMed

Publication types

Substances